Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ark Bio to Release Positive Clinical Data on RSV Candidate

publication date: Oct 31, 2018

Ark Biosciences, a Shanghai-Suzhou clinical-stage biotech, will release unblinded clinical efficacy results from a global trial of ziresovir, a treatment for RSV in hospitalized infants. The results, which come from Part 1 of a global Phase II proof-of-concept ziresovir trial, will be presented at two scientific meetings over the next two weeks. Ark in-licensed global rights to the candidate from Roche in 2014. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital